Association Between Serum Irisin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis

Abstract

Irisin, an emerging adipokine, has been involved in the pathogenesis of type 2 diabetes mellitus (T2DM). However, previous studies evaluating the association between irisin and diabetic nephropathy (DN) showed inconsistent results. We performed a meta-analysis to evaluate the above association. Matched case-control studies evaluating the difference of serum irisin between T2DM patients with and without DN were identified via systematic search of PubMed, Embase, Cochranes’ Library, China National Knowledge Infrastructure, and WanFang databases from inception to December 5, 2020. A random-effects model or a fixed-effects model was used to pool the results according to the heterogeneity. Overall, thirteen matched case-control studies including 1735 T2DM patients were included. Results of meta-analysis showed that compared to T2DM patients with normoalbuminuria, those with microalbuminuria [10 studies, standard mean difference (SMD): 1.12, 95% confidence interval (CI): 0.48–1.77, p<0.001; I²=94%] and macroalbuminuria (10 studies, SMD: 1.86, 95% CI: 0.93–2.79, p<0.001; I²=97%) had significantly lower serum irisin. Besides, the serum level of irisin was significantly lower in T2DM patients with macroalbuminuria than those with microalbuminuria (10 studies, SMD: 0.91, 95% CI: 0.44–1.38, p<0.001; I²=90%). In addition, patients with estimated glomerular infiltration rate (eGFR)<60 ml/min 1.73 m² had lower serum irisin compared to those with eGFR≥60 ml/min 1.73 m² (4 studies, SMD: 0.89, 95% CI: 0.32–1.46, p=0.002; I²=91%). In conclusion, serum irisin may be associated with albuminuria and reduced eGFR in T2DM patients.

Key words

type 2 diabetes mellitus - diabetic nephropathy - irisin - adipokines - meta-analysis

Publication History

Received: 10 January 2021

Accepted after revision: 01 April 2021

Article published online:
07 May 2021

• References

• 1 Bonner R, Albajrami O, Hudspeth J. et al. Diabetic Kidney Disease. Prim Care 2020; 47: 645-659
• 2 Pugliese G, Penno G, Natali A. et al. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”. Nutr Metab Cardiovasc Dis 2019; 29: 1127-1150
• 3 Abdelhafiz AH. Diabetic kidney disease in older people with type 2 diabetes mellitus: Improving prevention and treatment options. Drugs Aging 2020; 37: 567-584
• 4 Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 2020; 22: 3-15
• 5 Zhang XX, Kong J, Yun K. Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: A meta-analysis of observational studies. J Diabetes Res. 2020 2315607.
• 6 Jerums G, Panagiotopoulos S, Premaratne E. et al. Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol 2009; 5: 397-406
• 7 Lin YC, Chang YH, Yang SY. et al. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc 2018; 117: 662-675
• 8 Fu H, Liu S, Bastacky SI. et al. Diabetic kidney diseases revisited: A new perspective for a new era. Mol Metab 2019; 30: 250-263
• 9 Maciorkowska M, Musialowska D, Malyszko J. Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. Adv Clin Exp Med 2019; 28: 1571-1575
• 10 Du XL, Jiang WX, Lv ZT. Lower circulating irisin level in patients with diabetes mellitus: A systematic review and meta-analysis. Horm Metab Res 2016; 48: 644-652
• 11 Perakakis N, Triantafyllou GA, Fernandez-Real JM. et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol 2017; 13: 324-337
• 12 Polyzos SA, Anastasilakis AD, Efstathiadou ZA. et al. Irisin in metabolic diseases. Endocrine 2018; 59: 260-274
• 13 Martinez Munoz IY, Camarillo Romero EDS, Garduno Garcia JJ. Irisin a novel metabolic biomarker: present knowledge and future directions. Int J Endocrinol. 2018 7816806.
• 14 Korta P, Pochec E, Mazur-Bialy A. Irisin as a multifunctional protein: implications for health and certain diseases. Medicina (Kaunas) 2019; 55: 485
• 15 Byun K, Lee S. The potential role of irisin in vascular function and atherosclerosis: A review. Int J Mol Sci 2020; 21: 7184
• 16 Zhang M, Chen P, Chen S. et al. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci 2014; 18: 1567-1572
• 17 Ali EY, Hegazy GA, Hashem EM. Evaluation of irisin, retinol-binding protein 4, and leptin serum levels as biomarkers of macrovascular complications involvement in Saudi type 2 diabetes mellitus. A case-control study. Saudi Med J 2020; 41: 1369-1374
• 18 Liu JJ, Liu S, Wong MD. et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complicat 2014; 28: 208-213
• 19 Wang HH, Zhang XW, Chen WK. et al. Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes. J Diabetes Complicat 2015; 29: 384-389
• 20 Hu W, Wang R, Li J. et al. Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy. Ann Clin Biochem 2016; 53: 67-74
• 21 Liu Y, Jian L, Pan J. Study on the correlation between serum irisin and type 2 diabetic nephropathy. Chongqing Med J 2016; 45: 4243-4245
• 22 Wang W, Wang S, Liu J. et al. The level of serum irisin and its influencing factors in diabetic kidney disease. Chin J Integr Tradit West Nephrol 2016; 17: 403-406
• 23 Khidr EG, Ali SS, Elshafey MM. et al. Association of irisin and FNDC5 rs16835198 G>T gene polymorphism with type 2 diabetes mellitus and diabetic nephropathy. An Egyptian pilot study. Gene 2017; 626: 26-31
• 24 Cha JJ, Min HS, Kim K. et al. Long-term study of the association of adipokines and glucose variability with diabetic complications. Korean J Intern Med 2018; 33: 367-382
• 25 Liu S, Duan R, Wu Y. et al. Correlation between irisin, betatrophin and type 2 diabetic nephropathy. Chin J Integr Tradit West Nephrol 2018; 19: 861-865
• 26 Shelbaya S, Abu Shady MM, Nasr MS. et al. Study of irisin hormone level in type 2 diabetic patients and patients with diabetic nephropathy. Curr Diabetes Rev 2018; 14: 481-486
• 27 Zhang Y, Chen Y, Huang Y. et al. Relationship between serum irisin and senile diabetic nephropathy. Chin J Pract Med 2018; 45: 1-4
• 28 Mageswari R, Sridhar MG, Nandeesha H. et al. Irisin and Visfatin Predicts Severity of Diabetic Nephropathy. Indian J Clin Biochem 2019; 34: 342-346
• 29 Xu Z, Jiang H, Chen X. et al. Correlation between irisin and type 2 diabetic nephropathy in elderly patients. Jiangsu Med J 2019; 45: 916-919
• 30 Chen J, Liu M, Shan X. et al. Correlations of serum irisin with serum uric acids and urinary albumin-creatinine ratio in patients with type 2 diabetes mellitus. Chin J Gerontol 2020; 40: 716-719
• 31 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012
• 32 Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. 2011 www.cochranehandbook.org
• 33 Jia W, Weng J, Zhu D. et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev 2019; 35: e3158
• 34 Buse JB, Wexler DJ, Tsapas A. et al. Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2019; 2020: 487-493
• 35 Wells GA, Shea B, O'Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
• 36 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 37 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
• 38 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
• 39 Peng H, Wang Q, Lou T. et al. Myokine mediated muscle-kidney crosstalk suppresses metabolic reprogramming and fibrosis in damaged kidneys. Nat Commun 2017; 8: 1493
• 40 Zhang R, Ji J, Zhou X. et al. Irisin Pretreatment Protects Kidneys against Acute Kidney Injury Induced by Ischemia/Reperfusion via Upregulating the Expression of Uncoupling Protein 2. Biomed Res Int 2020; 6537371
• 41 Liu Y, Fu Y, Liu Z. et al. Irisin is induced in renal ischemia-reperfusion to protect against tubular cell injury via suppressing p53. Biochim Biophys Acta Mol Basis Dis 2020; 1866: 165792
• 42 Jin YH, Li ZY, Jiang XQ. et al. Irisin alleviates renal injury caused by sepsis via the NF-kappaB signaling pathway. Eur Rev Med Pharmacol Sci 2020; 24: 6470-6476
• 43 Zhang J, Bi J, Ren Y. et al. Involvement of GPX4 in irisin's protection against ischemia reperfusion-induced acute kidney injury. J Cell Physiol 2021; 236: 931-945
• 44 Jia J, Yu F, Wei WP. et al. Relationship between circulating irisin levels and overweight/obesity: A meta-analysis. World J Clin Cases 2019; 7: 1444-1455